Alexion Pharmaceuticals, Inc.

Bayer Corporation

Bayer Healthcare LLC

Miles Inc.

Aerovance, Inc.

Paul P Tamburini

Douglas L Sheridan

Russell P Rother

Bruce A Andrien, Jr

Yuchun Zhang

Yi Wang

Gary Davis

Katherine A Delaria

Daniel K Muller

Christopher W Marlor

Julian Chandler

Nimish Gera

Bridget Puffer

Siddharth Jindal

Rudolf H Hanko

Timothy McCabe

Edward D Huguenel

Lila Adnane

Jeffrey William Hunter

Walter C Voegtli

Sha Ha

Gerald Ranges

Taneisha Ann-Tanara Mack

Pamela Trail

Thomas Gould

Kimberly Ann Fallon

Kathryn M Bausch

Robert N Dreyer

Bruce A Andrien

Timothy Mccabe

The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.

Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof

The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.

Anti-C5 antibodies having improved pharmacokinetics

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Anti-C5A antibodies

Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.

Monovalent anti-properdin antibodies and antibody fragments

Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies

Anti-C5a antibodies

Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies

Methods of producing anti-C5a antibodies

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Methods of treating complement-associated disorders with anti-C5a antibodies

Nucleic acids encodng anti-C5A antibodies

Growing community of inventors

Kensington, CT, United States of America

Paul P Tamburini